Cargando…

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated

BACKGROUND: Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying molecular characteristics of primary and metastatic disease must be e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krakstad, Camilla, Birkeland, Even, Seidel, Danila, Kusonmano, Kanthida, Petersen, Kjell, Mjøs, Siv, Hoivik, Erling A., Wik, Elisabeth, Halle, Mari Kyllesø, Øyan, Anne M., Kalland, Karl-Henning, Werner, Henrica Maria Johanna, Trovik, Jone, Salvesen, Helga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531332/ https://www.ncbi.nlm.nih.gov/pubmed/23300780 http://dx.doi.org/10.1371/journal.pone.0052795

Ejemplares similares

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Switch in FOXA1 Status Associates with Endometrial Cancer Progression
por: Tangen, Ingvild Løberg, et al.
Publicado: (2014)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis
por: Bredin, Hanna K., et al.
Publicado: (2023)

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer
por: Wagner-Larsen, Kari S., et al.
Publicado: (2022)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

High visceral fat percentage is associated with poor outcome in endometrial cancer
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
por: Berg, Hege F., et al.
Publicado: (2020)

Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
por: Mazloumi Gavgani, Fatemeh, et al.
Publicado: (2018)

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer
por: Berg, Anna, et al.
Publicado: (2016)

Blood Metabolites Associate with Prognosis in Endometrial Cancer
por: Strand, Elin, et al.
Publicado: (2019)

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
por: Gibson, William J., et al.
Publicado: (2016)

An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer
por: Jacob, Havjin, et al.
Publicado: (2021)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value
por: Berg, Hege F., et al.
Publicado: (2022)

Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus
por: Miranda, Ludmilla Queirós, et al.
Publicado: (2013)

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
por: Mauland, K K, et al.
Publicado: (2011)

Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer
por: Hodneland, Erlend, et al.
Publicado: (2022)

What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
por: Lura, Njål, et al.
Publicado: (2022)

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
por: Kompier, Lucie C., et al.
Publicado: (2010)

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
por: Karlsson, Thomas, et al.
Publicado: (2016)

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fn435r73a76qi1q8pnov8vgi1s